{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:36:18Z","timestamp":1793723778632,"version":"4.6.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cell therapies are based on the genetic modification of the T cell receptor of a patient\u2019s own T cells. The resulting CAR T cells cytotoxic response is redirected against a specific tumor antigen. This innovative immunotherapy has been used successfully to treat blood malignancies, and it is also being developed as treatment for solid tumors. CAR T cells can lead to immune related adverse outcomes associated with an unwanted immune response in the host, ranging from acute events to those sustained with time, such as antidrug antibody (ADA) development, which can impact the efficacy and persistence of the CAR T cells once administered to the patient. The development of ADAs as response to a drug treatment is not exclusive to CAR T cells, and evidence of their production has been long acknowledged. While traditional types of analysis aim to measure the presence of ADAs by immunoassay methods, with the therapeutic agent being cells, the use of a flow cytometry approach has become the obvious choice for detection and quantification of ADAs against CAR T cells products, as well as any other cell therapies. Here, we present the results of the development of a flow cytometry method to measure ADAs using CAR T cells with an assay to detect the binding of an ADA-like molecule to the CAR T cells in a dose-dependent manner. This method allowed for quantification of ADAs and determination of the assay values needed for potential ADA measurement in clinical samples.<\/jats:p>","DOI":"10.1093\/immhor\/vlag011","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:25:47Z","timestamp":1777119947000},"source":"Crossref","is-referenced-by-count":0,"title":["Development of a flow cytometry method to measure antidrug antibodies against CAR T cells"],"prefix":"10.1093","volume":"10","author":[{"given":"Georgia","family":"Day","sequence":"first","affiliation":[{"name":"Immunology and Immunotoxicology Department, Labcorp , Huntingdon,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"S\u00e1nchez-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Immunology and Immunotoxicology Department, Labcorp , Huntingdon,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Seavers","sequence":"additional","affiliation":[{"name":"Immunology and Immunotoxicology Department, Labcorp , Huntingdon,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cadwallader","sequence":"additional","affiliation":[{"name":"Immunology and Immunotoxicology Department, Labcorp , Huntingdon,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Morgado-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Immunology and Immunotoxicology Department, Labcorp , Huntingdon,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"2026110311223083700_vlag011-B1","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"New England J Med"},{"key":"2026110311223083700_vlag011-B2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/357011a0","article-title":"Coley\u2019s toxins in perspective","volume":"357","author":"Starnes","year":"1992","journal-title":"Nature"},{"key":"2026110311223083700_vlag011-B3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/360023b0","article-title":"Coley\u2019s toxins","volume":"360","author":"Starnes","year":"1992","journal-title":"Nature"},{"key":"2026110311223083700_vlag011-B4","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front Immunol"},{"key":"2026110311223083700_vlag011-B5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2026110311223083700_vlag011-B6","doi-asserted-by":"crossref","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"2026110311223083700_vlag011-B7","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.3390\/jcm13113202","article-title":"CAR-T-cell-based cancer immunotherapies: potentials, limitations, and future prospects","volume":"13","author":"Choudhery","year":"2024","journal-title":"J Clin Med"},{"key":"2026110311223083700_vlag011-B8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"key":"2026110311223083700_vlag011-B9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2026110311223083700_vlag011-B10","doi-asserted-by":"crossref","first-page":"886546","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front Immunol"},{"key":"2026110311223083700_vlag011-B11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4155\/bio-2022-0081","article-title":"2021 White paper on recent issues in bioanalysis: TAb\/NAb, viral vector CDx, shedding assays; CRISPR\/Cas9 & CAR-T immunogenicity; PCR & vaccine assay performance; ADA assay comparability & cut point appropriateness (Part 3 - recommendations on gene therap","volume":"14","author":"Loo","year":"2022","journal-title":"Bioanalysis"},{"key":"2026110311223083700_vlag011-B12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40259-019-00354-5","article-title":"Immunogenicity of chimeric antigen receptor T-Cell therapeutics","volume":"33","author":"Gorovits","year":"2019","journal-title":"BioDrugs"},{"key":"2026110311223083700_vlag011-B13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026110311223083700_vlag011-B14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.17544","article-title":"Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells","volume":"195","author":"Sanber","year":"2021","journal-title":"Br J Haematol"},{"key":"2026110311223083700_vlag011-B15","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/jssc.202200112","article-title":"Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: a review","volume":"45","author":"Suh","year":"2022","journal-title":"J Sep Sci"},{"key":"2026110311223083700_vlag011-B16"},{"key":"2026110311223083700_vlag011-B17","doi-asserted-by":"crossref","first-page":"112692","DOI":"10.1016\/j.jim.2019.112692","article-title":"A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel","volume":"476","author":"Potthoff","year":"2020","journal-title":"J Immunol Methods"},{"key":"2026110311223083700_vlag011-B18","doi-asserted-by":"crossref","first-page":"e13549","DOI":"10.15252\/emmm.202013549","article-title":"Flow cytometry multiplexed method for the detection of neutralizing human antibodies to the native SARS-CoV-2 spike protein","volume":"13","author":"Horndler","year":"2021","journal-title":"EMBO Mol Med"},{"key":"2026110311223083700_vlag011-B19","doi-asserted-by":"crossref","first-page":"1121020","DOI":"10.3389\/fmed.2023.1121020","article-title":"Anti-ROR1 CAR-T cells: architecture and performance","volume":"10","author":"Osorio-Rodr\u00edguez","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026110311223083700_vlag011-B20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41420-024-02239-1","article-title":"Therapeutic advances in the targeting of ROR1 in hematological cancers","volume":"10","author":"Tigu","year":"2024","journal-title":"Cell Death Discov"},{"key":"2026110311223083700_vlag011-B21","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood.2021014760","article-title":"ROR1: an orphan becomes apparent","volume":"140","author":"Kipps","year":"2022","journal-title":"Blood"},{"key":"2026110311223083700_vlag011-B22","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/07853890310012094","article-title":"Leukemia-lymphoma cell lines as model systems for hematopoietic research","volume":"35","author":"Drexler","year":"2003","journal-title":"Ann Med"},{"key":"2026110311223083700_vlag011-B23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jcp.18.3.261","article-title":"A study of malignant tumours in Nigeria by short-term tissue culture","volume":"18","author":"Pulvertaft","year":"1965","journal-title":"J Clin Pathol"},{"key":"2026110311223083700_vlag011-B24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.leu.2403534","article-title":"Raji revisited: cytogenetics of the original Burkitt\u2019s lymphoma cell line","volume":"19","author":"Karpova","year":"2005","journal-title":"Leukemia"},{"key":"2026110311223083700_vlag011-B25","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"2026110311223083700_vlag011-B26","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1208\/s12248-017-0107-3","article-title":"Recommendations for systematic statistical computation of immunogenicity cut points","volume":"19","author":"Devanarayan","year":"2017","journal-title":"Aaps J"},{"key":"2026110311223083700_vlag011-B27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1208\/s12248-020-00510-8","article-title":"Are lessons learned in setting cut points for detection of anti-drug antibodies also useful in serology assays for robust detection of SARS-CoV-2 reactive antibodies?","volume":"22","author":"Bowsher","year":"2020","journal-title":"AAPS J"},{"key":"2026110311223083700_vlag011-B28"},{"key":"2026110311223083700_vlag011-B29","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next?","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026110311223083700_vlag011-B30","doi-asserted-by":"crossref","first-page":"1399544","DOI":"10.3389\/fonc.2024.1399544","article-title":"Challenges and innovations in CAR-T cell therapy: a comprehensive analysis","volume":"14","author":"Luo","year":"2024","journal-title":"Front Oncol"},{"key":"2026110311223083700_vlag011-B31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: the next revolution in cancer treatment","volume":"22","author":"Al-Haideri","year":"2022","journal-title":"Cancer Cell Int"},{"key":"2026110311223083700_vlag011-B32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10238-024-01442-9","article-title":"Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy","volume":"24","author":"Rehman","year":"2024","journal-title":"Clin Exp Med"},{"key":"2026110311223083700_vlag011-B33","doi-asserted-by":"crossref","first-page":"1368732","DOI":"10.3389\/fonc.2024.1368732","article-title":"Prospects and challenges of CAR-T cell therapy combined with ICIs","volume":"14","author":"Lv","year":"2024","journal-title":"Front Oncol"},{"key":"2026110311223083700_vlag011-B34","first-page":"21","article-title":"CAR T-Cell therapy: adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"2026110311223083700_vlag011-B35","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/acem.13443","article-title":"Immune-related adverse events in cancer patients","volume":"25","author":"Pallin","year":"2018","journal-title":"Acad Emerg Med"},{"key":"2026110311223083700_vlag011-B36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/antib7020019","article-title":"Anti-drug antibodies: Emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity","volume":"7","author":"Pratt","year":"2018","journal-title":"Antibodies"},{"key":"2026110311223083700_vlag011-B37","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/1078-0432.CCR-21-0168","article-title":"Antidrug antibodies and drug development: challenges in the immunotherapy era","volume":"27","author":"De Speville","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026110311223083700_vlag011-B38","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"key":"2026110311223083700_vlag011-B39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"key":"2026110311223083700_vlag011-B40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/2472555218768745","article-title":"High-throughput flow cytometric method for the simultaneous measurement of CAR-T cell characterization and cytotoxicity against solid tumor cell lines","volume":"23","author":"Martinez","year":"2018","journal-title":"SLAS Discovery"},{"key":"2026110311223083700_vlag011-B41","first-page":"A8","article-title":"8 Multiparameter characterization of CAR T cells","volume":"9","author":"Wang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026110311223083700_vlag011-B42","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cyto.b.21941","article-title":"Monitoring CAR T-cells using flow cytometry","volume":"100","author":"Demaret","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"2026110311223083700_vlag011-B43","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","article-title":"Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R\/R DLBCL","volume":"7","author":"Blumenberg","year":"2023","journal-title":"Blood Adv"},{"key":"2026110311223083700_vlag011-B44","doi-asserted-by":"crossref","first-page":"658314","DOI":"10.3389\/fimmu.2021.658314","article-title":"Advanced flow cytometry assays for immune monitoring of CAR-T cell applications","volume":"12","author":"Blache","year":"2021","journal-title":"Front Immunol"},{"key":"2026110311223083700_vlag011-B45","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1182\/blood-2023-188349","article-title":"Quantification of ADA of humanized CD19 CAR-T cell therapy in R\/R LBCL","volume":"142","author":"Huang","year":"2023","journal-title":"Blood"},{"key":"2026110311223083700_vlag011-B46","doi-asserted-by":"crossref","first-page":"830773","DOI":"10.3389\/fimmu.2022.830773","article-title":"Monitoring of circulating CAR T cells: validation of a flow cytometric assay, cellular kinetics, and phenotype analysis following tisagenlecleucel","volume":"13","author":"Peinelt","year":"2022","journal-title":"Front Immunol"},{"key":"2026110311223083700_vlag011-B47","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/bloodadvances.2023012073","article-title":"Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma","volume":"8","author":"Denlinger","year":"2024","journal-title":"Blood Adv"},{"key":"2026110311223083700_vlag011-B48","doi-asserted-by":"crossref","first-page":"101249","DOI":"10.1016\/j.omtm.2024.101249","article-title":"Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence","volume":"32","author":"Cappabianca","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026110311223083700_vlag011-B49","doi-asserted-by":"crossref","first-page":"1298598","DOI":"10.3389\/fimmu.2024.1298598","article-title":"Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time","volume":"15","author":"Odak","year":"2024","journal-title":"Front Immunol"},{"key":"2026110311223083700_vlag011-B50","doi-asserted-by":"crossref","first-page":"A66","DOI":"10.1136\/jitc-2024-SITC2024.0059","volume-title":"Regular and young investigator award abstracts","author":"Sakellariou-Thompson","year":"2024"},{"key":"2026110311223083700_vlag011-B51","doi-asserted-by":"publisher","first-page":"10263","DOI":"10.3390\/ijms251910263","article-title":"Using spectral flow cytometry for CAR T-cell clinical trials: Game changing technologies enabling novel therapies","volume":"25","author":"Beadnell","year":"2024","journal-title":"IJMS"}],"container-title":["ImmunoHorizons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/10\/4\/vlag011\/68159046\/vlag011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/10\/4\/vlag011\/68159046\/vlag011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:22:51Z","timestamp":1793722971000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article\/doi\/10.1093\/immhor\/vlag011\/8662415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/immhor\/vlag011","relation":{},"ISSN":["2573-7732"],"issn-type":[{"value":"2573-7732","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4]]},"article-number":"vlag011"}}